{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:45:07Z","timestamp":1784360707675,"version":"3.55.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.<\/jats:p>","DOI":"10.1001\/jamaneurol.2023.0815","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:32:40Z","timestamp":1682350360000},"page":"659","source":"Crossref","is-referenced-by-count":27,"title":["Advocating for Demonstration of Disease Modification\u2014Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?"],"prefix":"10.1001","volume":"80","author":[{"given":"Vincent","family":"Planche","sequence":"first","affiliation":[{"name":"Centre National de la Recherche Scientifique, Universit\u00e9 de Bordeaux, Institut des Maladies Neurod\u00e9g\u00e9neratives, Bordeaux, France"},{"name":"Centre M\u00e9moire Ressources Recherches, P\u00f4le de Neurosciences Cliniques, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Villain","sequence":"additional","affiliation":[{"name":"AP-HP.Sorbonne Universit\u00e9, Institut de la M\u00e9moire et de la Maladie d\u2019Alzheimer, D\u00e9partement de Neurologie, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"},{"name":"Sorbonne Universit\u00e9, Institut national de la Sant\u00e9 et de la Recherche Medical (INSERM) U1127, Centre National de la Recherche Scientifique (CNRS) 7225, Institut du Cerveau\u2014ICM, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"nvp230006r1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"nvp230006r2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","article-title":"Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype.","volume":"15","author":"Vermunt","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"10","key":"nvp230006r3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.neurol.2022.06.012","article-title":"High-clearance anti-amyloid immunotherapies in Alzheimer\u2019s disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.","volume":"178","author":"Villain","year":"2022","journal-title":"Rev Neurol (Paris)"},{"issue":"2","key":"nvp230006r4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.14283\/jpad.2017.12","article-title":"Defining disease modifying therapy for Alzheimer\u2019s disease.","volume":"4","author":"Cummings","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"nvp230006r5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer\u2019s disease.","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"issue":"2","key":"nvp230006r6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease.","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"18","key":"nvp230006r7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease.","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"nvp230006r9","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1111\/ene.v28.9","article-title":"Brain volume loss due to donanemab.","volume":"28","author":"Ayton","year":"2021","journal-title":"Eur J Neurol"},{"issue":"5","key":"nvp230006r10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson\u2019s disease.","volume":"387","author":"Lang","year":"2022","journal-title":"N Engl J Med"},{"key":"nvp230006r8","author":"Iwatsubo","year":"2022"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2803745\/jamaneurology_planche_2023_vp_230006_1688145165.98844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T15:43:16Z","timestamp":1689003796000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2803745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.0815","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}